Alternatives to RayBiotech Quantibody — Quantitative multiplex antibody arrays for high-throughput proteomics
Researchers searching for RayBiotech Quantibody alternatives are usually looking for other multiplex protein quantification platforms that deliver similar throughput without the same array format or pricing structure. Quantibody arrays allow simultaneous measurement of many analytes from limited samples using a glass-slide format that requires only standard fluorescence scanners. Common reasons for exploring replacements include needs for higher plexity, different detection chemistry, broader species coverage, or easier data analysis pipelines. Alternatives range from bead-based suspension arrays to proximity extension assays and electrochemiluminescence platforms. Each option differs in sample volume requirements, dynamic range, custom content flexibility, and whether the system is open or closed. Evaluating these factors helps labs choose the best fit for biomarker discovery, inflammation profiling, or pathway analysis projects that were previously run on Quantibody arrays.

Olink Explore uses proximity extension assay technology for high-plex protein biomarker discovery across thousands of targets. It excels in large population studies with strong reproducibility but typically charges higher per-sample fees than Nomic Bio and provides relative rather than absolute quantification. Turnaround can extend beyond Nomic's one-week service for equivalent cohort sizes.
Olink ExploreOlink Explore uses proximity extension assay technology for high-plex protein biomarker discovery across thousands of targets. It excels in large population studies with strong reproducibility but typically charges higher per-sample fees than Nomic Bio and provides relative rather than absolute quantification. Turnaround can extend beyond Nomic's one-week service for equivalent cohort sizes.
SomaScanSomaScan employs aptamer-based capture for broad proteome profiling of over 7000 proteins from small sample volumes. It offers exceptional depth for discovery but lacks Nomic Bio's absolute quantification, lower cost structure, and rapid high-throughput service model suited to functional secretome studies.
Luminex xMAPLuminex bead-based multiplexing supports customizable panels up to several hundred analytes with widespread lab adoption. While flexible, it generally shows lower specificity than nELISA and requires more manual workflow, making it less ideal than Nomic for large-scale absolute quantification projects.
Quanterix Simoa delivers ultra-sensitive single-molecule detection for low-abundance proteins, often used in neurology and immunology. It provides excellent sensitivity but at higher cost per sample and lower plexity than Omni 1000, limiting its use for broad affordable profiling.
Traditional ELISA kits from Thermo Fisher offer validated single or low-plex protein measurements with absolute quantification. They remain cost-effective for small studies yet cannot match Nomic Bio's multiplexing scale, throughput, or panel flexibility for discovery workflows.
MSD electrochemiluminescence assays enable multiplex detection with good dynamic range and sensitivity. The platform supports custom panels but typically involves higher instrumentation costs and slower processing than Nomic's automated service for thousands of samples.
Abcam FirePlexAbcam FirePlex provides bead-based multiplex immunoassays focused on inflammation and oncology markers. It offers solid reproducibility for mid-plex work but lacks the absolute quantification, cost efficiency at scale, and secretome-optimized library found in Nomic Omni 1000.
Bio-Rad Bio-Plex systems run Luminex-style bead assays for cytokine and signaling protein panels. While accessible for many labs, they require more hands-on time and deliver lower throughput than Nomic's fully automated nELISA service with expert analysis included.
Proteome Sciences offers mass spectrometry-based proteomics services with broad coverage and biomarker expertise. While strong for unbiased discovery, the approach is slower and more expensive per sample than Nomic Bio's targeted, affordable, absolute-quantified nELISA platform for translational cohorts.